Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss. The drug remains investigational and is not FDA-approved.
A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
